AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
20.58
+1.52 (7.97%)
Apr 17, 2025, 4:00 PM EDT - Market closed
AnaptysBio Employees
AnaptysBio had 136 employees as of December 31, 2024. The number of employees increased by 19 or 16.24% compared to the previous year.
Employees
136
Change (1Y)
19
Growth (1Y)
16.24%
Revenue / Employee
$671,176
Profits / Employee
-$1,067,875
Market Cap
630.20M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ANAB News
- 25 days ago - Anaptys Announces Stock Repurchase Plan - GlobeNewsWire
- 7 weeks ago - Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Anaptys Announces Participation in March Investor Conferences - GlobeNewsWire
- 2 months ago - Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - GlobeNewsWire
- 2 months ago - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - GlobeNewsWire
- 2 months ago - Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - GlobeNewsWire
- 3 months ago - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire